author-photo

Diana S.Y. Abdulla

University of Cologne

20

Papers

59

Citations

Citation Trend

Filter By

Papers (12) Sort By

Journal Conference Others

Motor, sensitive, and vegetative recovery in rats with compressive spinal-cord injury after combined treatment with erythropoietin and whole-body vibration.

2021 Restorative Neurology and Neuroscience
Show All
- Source
- Cite
- Save
Citations (0)
Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations

2020 Lung Cancer
Show All
- Source
- Cite
- Save
Citations (1)
Abstract CT255: EATON: A phase I dose-escalation trial of nazartinib (EGF816) and trametinib in EGFR-mutant NSCLC

2020 Tumor Biology
Show All
- Source
- Cite
- Save
Citations (0)
OA15.05 BIOLUMA: A Phase II Trial of Nivolumab and Ipilimumab in Lung Cancer – Prospective Evaluation of TMB in SCLC Patients

2019 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (1)
OTHR-14. TREATMENT MONITORING OF IMMUNOTHERAPY AND TARGETED THERAPY USING FET PET IN PATIENTS WITH MELANOMA AND LUNG CANCER BRAIN METASTASES: INITIAL EXPERIENCES

2019 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (0)
Acquired resistance to MET inhibition in MET driven NSCLC.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Overcoming acquired osimertinib-resistance in EGFR-mutant advanced non-small lung cancer mediated by activating BRAF V600E mutation.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Monitoring Treatment Response to Erlotinib in EGFR-mutated Non–small-cell Lung Cancer Brain Metastases Using Serial O-(2-[18F]fluoroethyl)-L-tyrosine PET

2019 Clinical Lung Cancer
Show All
- Source
- Cite
- Save
Citations (6)
Treatment monitoring of immunotherapy and targeted therapy using FET PET in patients with melanoma and lung cancer brain metastases: Initial experiences.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
EATON: An open-label, multicenter, phase I dose-escalation trial of nazartinib (EGF816) and trametinib in patients with EGFR-mutant non-small cell lung cancer – preliminary data on safety and tolerability.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)